Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Eric ANGEVIN"'
Autor:
Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Ivuxolimab (PF-04518600) and utomilumab (PF-05082566) are humanized agonistic IgG2 monoclonal antibodies against OX40 and 4-1BB, respectively. This first-in-human, multicenter, open-label, phase I, dose-escalation/dose-expansion study expl
Externí odkaz:
https://doaj.org/article/ccd14bbe12da44b9bec3de265e3da2d8
Autor:
Yutaro Kaneko, Ryo Hatano, Naoto Hirota, Nicolas Isambert, Véronique Trillet-Lenoir, Benoit You, Jérôme Alexandre, Gérard Zalcman, Fanny Valleix, Thomas Podoll, Yoshimi Umezawa, Seiichi Takao, Satoshi Iwata, Osamu Hosono, Tetsuo Taguchi, Taketo Yamada, Nam H. Dang, Kei Ohnuma, Eric Angevin, Chikao Morimoto
Publikováno v:
Biomarker Research, Vol 9, Iss 1, Pp 1-13 (2021)
Abstract Background The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I
Externí odkaz:
https://doaj.org/article/869532e7d9924a45b065a8c40a83cd05
Autor:
D. Ross Camidge, MD, PhD, Fabrice Barlesi, MD, PhD, Jonathan W. Goldman, MD, Daniel Morgensztern, MD, Rebecca Heist, MD, MPH, Everett Vokes, MD, Eric Angevin, MD, PhD, David S. Hong, MD, Igor I. Rybkin, MD, Minal Barve, MD, Todd M. Bauer, MD, Angelo Delmonte, MD, Martin Dunbar, DrPH, Monica Motwani, PhD, Apurvasena Parikh, PhD, Elysa Noon, PhD, Jun Wu, MD, Vincent Blot, PhD, Karen Kelly, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100262- (2022)
Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not
Externí odkaz:
https://doaj.org/article/5db379369d064b09bb9b7152b523f622
Autor:
Etienne Rouleau, Jean-Yves Scoazec, Aurélien Marabelle, Benjamin Besse, David Planchard, Jack Pollard, Angelique Biancotto, Marielle Chiron, Nathalie Chaput-Gras, DIB Colette, Eladio Marquez, Joon Sang Lee, Shu Yan, Cecile Combeau, Félix Blanc-Durand, Mihaela Aldea, Ludovic Lacroix, Saloomeh Rafie, Eric Angevin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/eec93b5ed5454a5b9e6ce5c07f948486
Autor:
Patricia Martin Romano, Eduardo Castanon, Antoine Hollebecque, Ludovic Lacroix, Nathalie Auger, Eric Angevin, Lambros Tselikas, Sami Ammari, Jean-Charles Soria, Christophe Massard
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 152-155 (2019)
Mesenchymal–epithelial transition factor (MET) amplification has been suggested either as a de novo or acquired mechanism of resistance to anti-epidermal growth factor receptor (anti-EGFR) therapy. However, even if MET amplification has been widely
Externí odkaz:
https://doaj.org/article/1642474e458b43f6bb34cbd5ae1dd354
Autor:
D. Ross Camidge, Fabrice Barlesi, Jonathan W. Goldman, Daniel Morgensztern, Rebecca Heist, Everett Vokes, Alex Spira, Eric Angevin, Wu-Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, Elysa Noon, Vincent Blot, Jun Wu, Karen Kelly
Publikováno v:
Journal of Clinical Oncology. 41:1105-1115
PURPOSE Overexpression of c-Met protein and epidermal growth factor receptor ( EGFR) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e2431abacc3768c259b0162a08fda6
https://doi.org/10.1200/jco.22.00739
https://doi.org/10.1200/jco.22.00739
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
This file provides supplementary methods for genomics, including TGS, CGH array, WES, RNAseq Analysis, IHC -MET.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba69ab65891380197866f102bd630ba
https://doi.org/10.1158/2159-8290.22532263.v1
https://doi.org/10.1158/2159-8290.22532263.v1
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
Individual PFS2 vs PFS1 profile plot. Each patient has been aligned at time 0 of PFS2 and sorted by the sum of PFS1 and PFS2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a319eaa8936dc0a6d0fd65acf61c1ec7
https://doi.org/10.1158/2159-8290.22532269.v1
https://doi.org/10.1158/2159-8290.22532269.v1
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
Genes that contain molecular alterations matched with therapies according to tumor type.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7a9c90c3275cb342e60c0f4a62dc43
https://doi.org/10.1158/2159-8290.22532272
https://doi.org/10.1158/2159-8290.22532272
Autor:
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, Christophe Massard
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c16525073b2d6d310034d67c993040
https://doi.org/10.1158/2159-8290.22532266
https://doi.org/10.1158/2159-8290.22532266